Investor Presentaiton slide image

Investor Presentaiton

Investor presentation ADA 2019 The PIONEER 6 trial investigated cardiovascular safety of oral semaglutide vs placebo Slide 15 PIONEER 6 trial design Oral semaglutide 14 mg + standard of care Randomised: 3,176 patients with type 2 diabetes Placebo + standard of care Trial objective 137 MACE Confirm the cardiovascular safety of oral semaglutide in patients with type 2 diabetes Inclusion criteria • Age ≥50 years and clinical evidence of CV disease or age ≥50 years and subclinical evidence of CV disease • Antidiabetic drug-naïve or current treatment with one or more oral or injectable antidiabetic agent(s) (excl. DPP-4 and GLP-1) PIONEER 6 headline results 21% non-significant reduction of primary endpoint¹ for oral semaglutide-treated patients compared to placebo-treated subjects (HR: 0.79) - CV death significant (HR: 0.49) Non-fatal MI - non-significant (HR: 1.18) Non-fatal stroke - non-significant (HR: 0.74) All-cause mortality - significant (HR: 0.51) Results were based on 137 MACE with median follow-up of 16 months PIONEER symposium on Tuesday June 11th from 9.45 - 11.45 (pacific time) 1 The primary endpoint of the PIONEER 6 trial was defined as the MACE composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. CV: cardiovascular; DPP-4: dipeptidyl peptidase-4 inhibitor; GLP-1: glucagon-like peptide-1; MACE: major cardiovascular event; HR: hazard ratio; MI: myocardial infarction; PIONEER: peptide innovation for early diabetes treatment novo nordisk
View entire presentation